The NASH pipeline is filled with promising compounds in various stages of development, from those targeting liver fat reduction to therapies aimed at fibrosis regression. Among the most notable drug classes making waves in the treatment of NASH are:
- Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
These drugs, including lanifibranor (Inventiva Pharma), work by targeting multiple pathways involved in fat metabolism, inflammation, and fibrosis. With favorable clinical trial results, PPAR agonists are among the front-runners in the NASH treatment race, offering a broad approach to managing NASH symptoms. - Fibroblast Growth Factor 21 (FGF21) Analogs
Therapies like efruxifermin (Akero Therapeutics) have shown impressive efficacy in reducing liver fat and fibrosis. FGF21 is a key regulator of metabolism, and its analogs are designed to regulate the processes contributing to NASH. These NASH upcoming therapies aim to address the root causes of liver damage, offering hope for more comprehensive treatment options. - Thyroid Hormone Receptor Agonists
Resmetirom (Madrigal Pharmaceuticals) is a selective thyroid hormone receptor-β (THR-β) agonist that has demonstrated promising results in reducing liver fat. With Phase 3 trials underway, this novel approach is poised to make a significant impact on the NASH treatment landscape.
With several NASH pipeline therapies showing great potential, the future of NASH treatment looks promising. As these novel drug classes move closer to regulatory approval, patients with NASH may soon have effective therapies to manage and reverse liver damage.
Latest Reports:-
Intraocular Lens Market | Surgical Robotic System Market | Surgical Sealant Market | Novel Drug Delivery Devices Market | Surgical Mask Respirator Market | Ventral Hernia Market | Antibody Drug Conjugate Market | Dyspepsia Market | Trichotillomania Market | Medical Marijuana Market
